Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CIK 2080343) reported 3 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-08-10). Recent activity: Buy BRVE (7.4M shares), Buy KLRA (9.5M shares), Buy KLRA (2.0M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Braveheart Bio, Inc. (BRVE) | 10% Owner | Buy | 7.4M | $0 |
| 2026-04-22 | Kailera Therapeutics, Inc. (KLRA) | 10% Owner | Buy | 9.5M | $0 |
| 2026-04-22 | Kailera Therapeutics, Inc. (KLRA) | 10% Owner | Buy | 2.0M | $0 |
Source: SEC Form 4 filings · as of 2026-08-10